REGULATORY INTELLIGENCE·Warning Letter
Biogen's Vumerity Recall: Dissolution Failures Highlight Critical Pharmaceutical Quality Control Risks
Biogen Inc. initiated a Class II recall for 5,307 bottles of Vumerity (diroximel fumarate) due to failed dissolution specifications. This event, terminated by the FDA, underscores the persistent quality control challenges in pharmaceutical manufacturing. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate supply chain disruptions and ensure product efficacy for patients.
90-Day Activity